Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2026-01-11 @ 8:54 PM
Study NCT ID:
NCT07005102
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2025-05-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-08-03
Start Date Type:
ACTUAL
Primary Completion Date:
2031-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-12
Completion Date Type:
ESTIMATED
First Submit Date:
2025-05-27
First Submit QC Date:
None
Study First Post Date:
2025-06-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-22
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL